Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer


24 Nov 2018


Poster display - Cocktail


Tumour Site

Breast Cancer


Sourav Nandi


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


S.K. Nandi1, R. Bhattacharya1, T. Roychowdhury2, U.K. Roy3, S. Chattopadhyay2, A. Mukhopadhyay4

Author affiliations

  • 1 Molecular Biology, Netaji Subhas Chandra Bose Cancer Research Institute, 700094 - Kolkata/IN
  • 2 Cancer Biology And Inflammatory Diseases, Indian Institute of Chemical Biology, 700032 - Kolkata/IN
  • 3 Pathology, Netaji Subhas Chandra Bose Cancer Research Institute, 700094 - Kolkata/IN
  • 4 Haemato Oncology, Netaji Subhas Chandra Bose Cancer Research Institute, 700094 - Kolkata/IN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 916


Emergence of drug resistant primary breast tumors has remained a major concern in disease handling. Breast cancer stem cells comprise a relatively less differentiated subpopulations of breast cancer with high expression of CD44, metastatic potential and drug recalcitrant, thus imparting major global concern in tackling breast cancer. Our work describe the effect of ethanolic extract of Anthocephalus cadamba (CLE) on breast cancer stem cell populations (CD44+/CD24- and/or EpCAM+) cultured ex-vivo.


Ethanolic leaf extract of Anthocephalus cadamba was made at a concentration of 10mg/ml. Anticancer effects of this extract was compared with the effect of Gemcitabine in breast cancer stem cells isolated from primary breast tumour. Breast tumor samples (n = 20) were homogenized with collagenase-dispase solution followed by trypsinization (1), plated (1x106cells/ml) in DMEM-F12 media with supplements and antibiotics. MTT assay was carried out following established protocol (2). Cells were cultured and treated with CLE or Gemicitabine at their IC-50 dosage. RNA extraction, semiquantitative RT-PCR and qRT-PCR for expression analysis of stem cell markers (SOX2 and NANOG1) was carried out following established protocol. Immunophenotyping to detect stem cell markers in both treated and untreated cells were carried out following established protocol.


Our data showed Gemcitabine, and CLE reflected 50% inhibitory effect at IC-50 doses of 50mM, 50mg/ml respectively (Fig 1). In both semiquantitative and q-RT-PCR, drug treatment resulted in reduction of copy number of SOX2 and NANOG1 amplicons (of 228, and 173bp respectively). (Fig 2). Immunophenotyping data showed, treatment with CLE showed 63% reduction of both CD44+ EpCAM+ populations (Fig 3).


Our data showed efficacy of CLE in attenuating breast cancer stem cells.

Editorial acknowledgement

We acknowledge Indian Council of Medical Research ( Memo No: 5/13/87/2013/NCD-III) for providing essential fund in carrying out this project. We acknowledge Mr Tanmay Dolui, Indian Institute of Chemical Biology for Technical assistance in running flow cytometer.

Clinical trial identification

Legal entity responsible for the study

Indian Council of Medical Research.


Indian Council of Medical Research.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.